Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea(R) (Paclical(R))

UPPSALA, Sweden, Feb. 8, 2016 /PRNewswire/ -- Oasmia Pharmaceutical AB (NASDAQ:  OASM) today announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for its lead cancer product Apealea (also known as Paclical).   (Logo: http://photos.prnewswi...